Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs (Q85001070)
Jump to navigation
Jump to search
scientific article published on 01 March 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs |
scientific article published on 01 March 2012 |
Statements
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs (English)
Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs (English)
1 reference
Roy Fleischmann
Maurizio Cutolo
Eun Bong Lee
Seth Sadis
David Gruben
Sriram Krishnaswami
Gene Wallenstein
Mark C. Genovese
Keith S. Kanik
Carol A. Connell
Bethanie E. Wilkinson
Samuel H. Zwillich
1 March 2012
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference